News and Publications
Publication Categories
7 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease
7 Hills Pharma receives a $3 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop the first vaccine for Chagas disease. This innovative vaccine combination with 7HP349 aims to protect millions from the Trypanosoma cruzi parasite and prevent severe outcomes of the disease.
7 Hills Pharma Receives $2M SBIR Grant from NCI to Launch Phase 1 Trials of Lead Immunostimulant to Augment Immuno-Oncology Drugs, COVID-19 and Flu Vaccines
7 Hills Pharma receives a $2M SBIR grant from the National Cancer Institute (NCI) to support Phase 1 trials of 7HP349, a small molecule designed to enhance immuno-oncology drugs and vaccines for COVID-19 and flu.
7 Hills Pharma Launches With $2 Million SBIR Grant in addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance
7 Hills Pharma secures a $2M SBIR grant from the NIH, alongside $4M in seed funding, to develop integrin activators that enhance cancer immunotherapy and improve checkpoint inhibitor effectiveness in treating solid tumors.